RE: Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living With Cancer Study

por Dekker, Joost, Stege, Claudia A M, Versteeg, Kathelijn S
Publicado 2021

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma

por Franssen, Laurens E., Stege, Claudia A. M., Zweegman, Sonja, van de Donk, Niels W. C. J., Nijhof, Inger S.
Publicado 2020

Midostaurin as the Most Likely Cause of Bilateral Adrenal Masses in a Patient with Acute Myeloid Leukemia

por Schutte, Tim, Stege, Claudia A. M., Smits, Mark M., Franssen, Laurens E., Donker, Marjolein L., de Leeuw, David C.
Publicado 2022

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma

por Bennink, M. Christine, Stege, Claudia A. M., Lissenberg-Witte, Birgit I., Oerlemans, Simone, Seefat, Maarten R., Sonneveld, Pieter, Zweegman, Sonja
Publicado 2022

Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma

por Mian, Hira, Grant, Shakira J., Engelhardt, Monika, Pawlyn, Charlotte, Bringhen, Sara, Zweegman, Sonja, Stege, Claudia A.M., Rosko, Ashley E., von Lilienfeld-Toal, Marie, Wildes, Tanya M.
Publicado 2020

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma

por Zajec, Marina, Frerichs, Kristine A., van Duijn, Martijn M., Nijhof, Inger S., Stege, Claudia A.M., Avet-Loiseau, Hervé, Luider, Theo M., de Rijke, Yolanda B., Jacobs, Joannes F.M., van de Donk, Niels W.C.J.
Publicado 2020

Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autolog...

por Zweegman, Sonja, Stege, Claudia A.M., Haukas, Einar, Schjesvold, Fredrik H., Levin, Mark-David, Waage, Anders, Leys, Rineke B.L., Klein, Saskia K., Szatkowski, Damian, Axelsson, Per, Do, Trung Hieu, Knut-Bojanowska, Dorota, van der Spek, Ellen, Svirskaite, Asta, Klostergaard, Anja, Salomo, Morten, Blimark, Celine, Ypma, Paula F., Mellqvist, Ulf-Hendrik, Poddighe, Pino J., Stevens-Kroef, Marian, van de Donk, Niels W.C.J., Sonneveld, Pieter, Hansson, Markus, van der Holt, Bronno, Abildgaard, Niels
Publicado 2020

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial

por Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka-Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie-Christiane, Timmers, Gert-Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark-David, Ypma, Paula F., Zweegman, Sonja
Publicado 2023